Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy Subjects

NCT02084953 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

59

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: BMS-791325
DRUG: Moxifloxacin
DRUG: Placebo matching BMS-791325

Sponsor

Bristol-Myers Squibb